North America Cardiac Assist Devices Market Industry: Market Size & Forecast 2026

Cardiac assist devices are mechanical systems designed to support or temporarily replace the pumping function of a failing heart. The North American market encompasses intra-aortic balloon pumps, cardiopulmonary bypass equipment, ventricular assistance devices, percutaneous heart pumps, and catheter-based assist pumps used during surgery, post-acute care, and chronic heart failure management. The United States accounts for the majority of regional demand due to its advanced healthcare infrastructure, favorable reimbursement environment, and high prevalence of cardiac conditions requiring intervention.

• •Market valued at approximately $2.22 billion in 2025 across the United States and Canada.
• •Device categories include intra-aortic balloon pumps, ventricular assist devices, cardiopulmonary bypass equipment, and percutaneous catheter pumps.
• •Used across cardiac surgery, acute care settings, and chronic heart failure management programs.

Rising incidence of coronary artery disease, heart failure, and other cardiovascular conditions is expanding the patient pool eligible for cardiac assist interventions. An aging demographic in both the United States and Canada is further amplifying demand, as cardiovascular risk factors such as hypertension, diabetes, and obesity continue to trend upward. Technological advancements in minimally invasive pump design, remote monitoring capabilities, and biocompatible materials are broadening clinical indications and improving patient outcomes, supporting greater device adoption across care settings.

• •Growing prevalence of heart failure and coronary artery disease is increasing the number of patients requiring mechanical circulatory support.
• •An aging North American population with higher rates of comorbid cardiovascular risk factors is expanding the addressable patient base.
• •Improvements in minimally invasive device technology, remote monitoring, and biocompatibility are widening clinical applications.

The market is segmented primarily by device type, intra-aortic balloon pumps, ventricular assist devices, cardiopulmonary bypass equipment, and catheter-based assist pumps, each serving distinct clinical use cases from intraoperative support to chronic bridge therapy. The United States dominates the North American landscape, supported by extensive hospital networks, robust research and development activity, and favorable government healthcare programs including Medicare reimbursement for approved devices. Canada represents a smaller but steadily growing segment, driven by universal healthcare coverage and increasing adoption of advanced cardiac technologies in major urban medical centers.

• •Device types include short-term circulatory support systems, ventricular assist devices, cardiopulmonary bypass equipment, and catheter-based pumps.
• •The United States is the dominant regional market, supported by advanced hospital infrastructure and favorable Medicare reimbursement policies.
• •Canada is a growing secondary market fueled by publicly funded healthcare adoption of advanced cardiac technologies.

What are the recent trends and outlook?

Ongoing innovation is pushing the market toward smaller, more efficient devices with reduced complication rates, particularly in the catheter-based and percutaneous pump segments. Integration of digital health technologies, including real-time telemetry and artificial intelligence-driven monitoring, is expected to improve post-implant patient management and reduce hospital readmissions. Over the 2025-2035 forecast horizon, the market is projected to maintain its 8.5% growth trajectory as emerging indications, expanding reimbursement pathways, and the increasing prevalence of advanced heart failure cases drive sustained demand across all major device categories.

• •Miniaturization and improved biocompatibility are leading to next-generation catheter pumps with lower complication profiles.
• •Digital health integration, including AI-enabled monitoring and telemetry, is becoming a differentiating feature among manufacturers.
• •The market is projected to sustain approximately 8.5% annual growth through the early 2030s as clinical adoption expands.